Company
Pipeline
Everist Genomics is leading the evolution of a new era in medicine: Personalized treatment tailored to each patient’s unique genetic make-up and disease characteristics.
Using proprietary applications based on molecular biomarkers and novel sensor technology, the company has developed and commercialized a portfolio of prognostic tests aimed at disease states with substantial unmet medical needs such as cancer and cardiovascular illness. Everist Genomics gives physicians crucial information about a patient’s health that can be used to make definitive treatment decisions and measure disease progression.
